timothy sykes logo
TCRT Stock Sees Volatile Spike As Traders Target Momentum Thumbnail
G Google News

TCRT Stock Sees Volatile Spike As Traders Target Momentum

BRYCE TUOHEY•UPDATED SEP. 18, 2026, 7:47 AM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Alaunos Therapeutics Inc. stocks have been trading up by 46.87 percent following highly positive sentiment around its cancer pipeline

Key Takeaways

  • TCRT shows a sharp premarket surge from under $2 to above $3 before pulling back, signaling heavy speculative trading.
  • Daily chart for Alaunos Therapeutics Inc. reveals a recent bounce from the low $1.20s back toward $1.60, after weeks of grinding lower.
  • Financials show tiny revenue, deep losses, and limited cash, putting TCRT firmly in high-risk biotech territory.
  • Balance sheet data suggest Alaunos Therapeutics Inc. may need fresh capital, a key factor for traders eyeing potential dilution.
  • Short-term traders are watching TCRT’s intraday support and resistance levels for momentum opportunities, not long-term fundamentals.

Candlestick Chart

Live Update At 07:47:24 EDT: On Friday, September 18, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 46.87%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

For active traders, TCRT is textbook speculative biotech. Alaunos Therapeutics Inc. posted just $5,000 in revenue, yet carries a sky‑high price-to-sales ratio above 1,500. That tells you right away the market isn’t paying for current business strength; it’s paying for hope and future potential.

Profitability numbers are ugly. TCRT shows a pretax margin around -3,300%, with return on equity and return on assets both deeply negative. Alaunos Therapeutics Inc. is burning cash, not generating it. The latest quarterly numbers show a net loss of about $952,000 and free cash flow of roughly -$300,000.

More Breaking News

On the balance sheet side, TCRT has only about $124,000 in cash against $864,000 in current liabilities and a current ratio near 0.8. Working capital is negative, and the quick ratio around 0.1 says Alaunos Therapeutics Inc. has very little liquid cushion. That’s why traders should always factor in financing risk here — TCRT lives in a world where secondary offerings, reverse splits, and restructuring moves are on the table. For short-term trading, the story is the chart, not the fundamentals.

Why Traders Are Watching TCRT Price Action

The reason TCRT is on day-traders’ screens right now is simple: volatility. Alaunos Therapeutics Inc. bounced from a recent daily close near $1.28 back to $1.60 the next day, a roughly 25% move off the lows in 24 hours. Zoom out a bit and you see a stock that slid from around $1.79–$1.80 down into the mid‑$1.20s over a few weeks, then suddenly caught a bid.

That “washout then bounce” pattern is common in beaten‑down biotech names. TCRT’s daily candles show repeated lower highs from late August into mid‑September, with the close drifting from about $1.79 on 2026/08/25 to $1.28 on 2026/09/16. Then Alaunos Therapeutics Inc. printed a strong green candle on 2026/09/17, closing near the top of the range at $1.60 after touching $1.65 intraday. That shift often signals shorts taking profits and momentum traders stepping in.

The intraday 5‑minute chart is even more dramatic. TCRT rips from sub‑$2 at 04:00 up to a spike high around $3.14 at 05:00, then fades back into the $2.20–$2.40 zone. That is a huge range in a short window. Alaunos Therapeutics Inc. shows multiple sharp wicks both up and down, telling you there’s aggressive buying and just as aggressive profit-taking.

For traders, that’s opportunity — but only with a tight risk plan. TCRT is acting like a low-float, story-driven biotech where liquidity can vanish as fast as it appears. You trade the levels, not the dream. Support in the low $2s and resistance near the mid‑$2s to $3 area are key zones to track if this volatility continues.

Conclusion

TCRT is not a slow, steady compounder. Alaunos Therapeutics Inc. is a classic speculative biotech with tiny revenue, big losses, and a thin cash position. The numbers scream risk: negative working capital, a current ratio below 1, and heavy dependence on external funding. Long term, those fundamentals are a headwind. Short term, they help explain why TCRT whipsaws so violently when traders crowd in.

The recent daily bounce from $1.28 to around $1.60, plus that wild premarket spike over $3, shows exactly how TCRT trades when momentum flips on. Alaunos Therapeutics Inc. can move 20–50% in a session, but those same moves work in both directions. This is where discipline matters most.

As Tim Sykes loves to remind traders, “Cut losses quickly — that’s rule number one if you want to stay in this game.” As millionaire penny stock trader and teacher Tim Sykes, says, “The goal is not to win every trade but to protect your capital and keep moving forward.”. With a name like TCRT, that rule isn’t optional. Traders focused on Alaunos Therapeutics Inc. should treat every setup as a trade, not a marriage. Respect the volatility, map your key levels, and size down so one bad candle doesn’t blow up your account. This is educational material, not advice — your job is to study the chart, understand the risk, and trade your own plan.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”